333 results on '"Linn, S.C."'
Search Results
2. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
3. Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial
4. Challenges towards an improved economic dispatch in an interconnected power system network
5. Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial
6. 163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)
7. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
8. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study
9. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial
10. 94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis
11. Blood-based LC-MS/MS analysis of steroids in prostate and ovarian cancer diagnostics: The importance of adequate bioanalytical methods
12. Improving immunotherapy for breast cancer patients
13. Treatment optimization for breast cancer patients according to age and tumor subtype
14. Personalizing breast cancer treatment with a focus on young women
15. Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study
16. St. Gallen endocrine response classes predict recurrence rates over time
17. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
18. Impact of lymphedema on health-related quality of life in early-stage breast cancer patients treated breast conserving therapy with or without sentinel lymph node biopsy: 2-year results from the randomized controlled trial BOOG2013–08
19. External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients
20. Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature
21. LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
22. 119P Characterisation of distinct subgroups of BRCA1-like triple-negative breast cancers with multiomics data analysis
23. 133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial
24. Prospective cost-effectiveness analysis of genomic profiling in breast cancer
25. Exploiting drug targets for development of rational combinations of classical and novel anticancer agents
26. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial
27. Exploiting drug targets for development of rational combinations of classical and novel anticancer agents
28. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer
29. Understanding the biology of triple-negative breast cancer
30. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
31. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
32. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy
33. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors
34. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
35. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry
36. LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)
37. 9P BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation
38. Breast cancer outcome in relation to bone mineral density and bisphosphonate use
39. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
40. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen
41. Measurement of the phase difference between short- and long-distance amplitudes in the B+ -> K+ mu(+) mu(-) decay
42. Cancer-immune interactions in ER-positive breast cancers
43. Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure
44. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
45. 159 (PB-072) Poster - Impact of lymphedema on health-related quality of life in early-stage breast cancer patients treated breast conserving therapy with or without sentinel lymph node biopsy: 2-year results from the randomized controlled trial BOOG2013–08
46. 13 (PB-009) Poster Discussion - External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients
47. 75P - Expression of XIST and 53BP1 as Predictive Markers in BRCA1 Deficient Breast Cancer
48. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
49. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
50. Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.